Critical molecular abnormalities in high-grade serous carcinoma of the ovary

Expert Reviews in Molecular Medicine

Volumn 10, Issue 22, 2008, Pages

  Köbel, Martin ^a,b   Huntsman, David ^a   Gilks, C Blake ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM DERIVATIVE; PROTEIN P53; RETINOBLASTOMA PROTEIN; ROSCOVITINE; TRANSCRIPTION FACTOR E2F; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER GRADING; CANCER INHIBITION; CANCER MORTALITY; CANCER RESEARCH; CARCINOGENESIS; CHEMOSENSITIVITY; CLINICAL FEATURE; CLINICAL TRIAL; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CYSTADENOCARCINOMA; FEMALE; GENETICS; METABOLISM; MUTATION; OVARY; OVARY TUMOR; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; HUMANS; MUTATION; OVARIAN NEOPLASMS; OVARY; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION;

EID: 49149110001     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S146239940800077X     Document Type: Review

References (92)

1. Tavasolli, F.A. and Devilee, P. (2003) World Health Organization Classification of Tumours. Tumours of the Breast and the Femal Genital Organs. IARC Press, WHO.
2. Auersperg, N. et al. (2001) Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr Rev 22, 255-288
3. Crum, C.P. et al. (2007) Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 5, 35-44
4. Gilks, C.B. et al. (2008) Tumor cell type can reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol (in press)
5. Seidman, J.D. et al. (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23, 41-44
6. Soslow, R.A. (2008) Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 27, 161-74
7. Takano, M. et al. (2006) Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94, 1369-1374
8. duBois, A. et al. (2003) A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95, 1320-1329
9. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. (2002) Lancet 360, 505-515
10. Shih, I. and Kurman, R.J. (2004) Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 164, 1511-1518
11. Han, G. et al. (2008) Interobserver variation in diagnosing mixed ovarian epithelial carcinoma with a clear cell component. Am J Surg Pathol 32, 955-964
12. Köbel, M. et al. (2008) A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol (in press)
13. Waldstrom, M. and Grove, A. (2005) Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med 129, 85-88
14. Al Hussaini, M. et al. (2004) WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44, 109-115
15. Malpica, A. et al. (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28, 496-504
16. Malpica, A. et al. (2007) Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31, 1168-1174
17. Singer, G. et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95, 484-486
18. Singer, G. et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29, 218-224
19. Crispens, M.A. et al. (2002) Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99, 3-10
20. Gershenson, D.M. et al. (2006) Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108, 361-368
21. Kurman, R.J. and Shih, I. (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27, 151-160
22. Gilks, C.B. (2004) Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 23, 200-205
23. Medeiros, F. et al. (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30, 230-236
24. Kindelberger, D.W. et al. (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 31, 161-169
25. Salvador, S. et al. (2008) Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol (in press)
26. Salvador, S. et al. (2008) The Fallopian Tube: Primary Site of Most Pelvic High-Grade Serous Carcinomas. Int J Gynecol Cancer (in press)
27. Tutt, A.N. et al. (2005) Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70, 139-148
28. Tutt, A. et al. (2001) Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 20, 4704-4716
29. Modan, B. et al. (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345, 235-240
30. Moslehi, R. et al. (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66, 1259-1272
31. Risch, H.A. et al. (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68, 700-710
32. Hilton, J.L. et al. (2002) Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94, 1396-1406
33. Press, J.Z. et al. (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8, 17
34. Shaw, P.A. et al. (2002) Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 21, 407-411
35. Foster, K.A. et al. (1996) Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 56, 3622-3625
36. Collins, N. et al. (1997) Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 76, 1150-1156
37. Brown, L.A. et al. (2006) Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100, 264-270
38. Raouf, A. et al. (2005) Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst 97, 1302-1306
39. Boyd, J. et al. (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283, 2260-2265
40. Ben David, Y. et al. (2002) Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20, 463-466
41. Quinn, J.E. et al. (2007) BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy. Clin Cancer Res 13, 7413-7420
42. Bhattacharyya, A. et al. (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275, 23899-23903
43. Narod, S.A. and Boyd, J. (2002) Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 14, 19-26
44. Farmer, H. et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921
45. Sakai, W. et al. (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120
46. Edwards, S.L. et al. (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115
47. Swisher, E.M. et al. (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68, 2581-2586
48. Vogelstein, B. and Kinzler, K.W. (2004) Cancer genes and the pathways they control. Nat Med 10, 789-799
49. Xing, D. and Orsulic, S. (2006) A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 66, 8949-8953
50. Flesken-Nikitin, A. et al. (2003) Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 63, 3459-3463
51. Wu, R. et al. (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/ Pten signaling pathways. Cancer Cell 11, 321-333
52. Garcia, A. et al. (2000) Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: Association with carcinomas with serous differentiation. Int J Gynecol Pathol 19, 152-157
53. Salani, R. et al. (2008) Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 18, 487-491
54. Havrilesky, L. et al. (2003) Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 21, 3814-3825
55. Moreno, C.S. et al. (2007) Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas. PLoS ONE 2, e441
56. Lavarino, C. et al. (2000) p53 gene status and response to platinum/ paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18, 3936-3945
57. Kandioler-Eckersberger, D. et al. (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6, 50-56
58. Crijns, A.P. et al. (2003) Prognostic factors in ovarian cancer: Current evidence and future prospects. In The ECCO 12 Educational Book of Eur J Cancer, pp. 127-145
59. Lassus, H. et al. (2003) Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 91, 504-512
60. Singer, G. et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29, 218-224
61. Ichimura, K. et al. (2000) Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60, 417-424
62. Bonome, T. et al. (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65, 10602-10612
63. Gilks, C.B. et al. (2005) Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 96, 684-694
64. Meinhold-Heerlein, I. et al. (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24, 1053-1065
65. Kommoss, S. et al. (2007) Independent prognostic significance of cell cycle regulator proteins p16(lNK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: A translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer 96, 306-313
66. Schultz, D.C. et al. (1995) Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 55, 2150-2157
67. Katsaros, D. et al. (2004) Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 94, 685-692
68. Armes, J.E. et al. (2005) Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 24, 363-368
69. Bali, A. et al. (2004) Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10, 5168-5177
70. Kim, T.M. et al. (1994) Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res 54, 605-609
71. Gorringe, K.L. et al. (2007) High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 13, 4731-4739
72. Harris, S.L. and Levine, A.J. (2005) The p53 pathway: Positive and negative feedback loops. Oncogene 24, 2899-2908
73. Nakayama, K. et al. (2007) Amplicon profiles in ovarian serous carcinomas. Int J Cancer 120, 2613-2617
74. Staebler, A. et al. (2006) Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 45, 905-917
75. Pelengaris, S. et al. (2002) c-MYC: More than just a matter of life and death. Nat Rev Cancer 2, 764-776
76. Farley, J. et al. (2003) Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: A Gynecologic Oncology Group study. Cancer Res 63, 1235-1241
77. Gabriel, B. et al. (2002) Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies. Onkologie 25, 240-247
78. Bookman, M.A. et al. (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21, 283-290
79. Riener, E.K. et al. (2004) The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: A multicenter study. Gynecol Oncol 95, 89-94
80. Tuefferd, M. et al. (2007) HER2 status in ovarian carcinomas: A multicenter GINECO study of 320 patients. PLoS ONE 2, e1138
81. Mayr, D. et al. (2006) HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 48, 149-156
82. Lee, C.H. et al. (2005) Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 24, 147-152
83. Berek, J.S. et al. (2003) Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 21, 168s-174s
84. Calzone, L. et al. (2008) A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol 4, 173
85. Dressman, H.K. et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25, 517-525
86. Agarwal, R. and Kaye, S.B. (2003) Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3, 502-516
87. Perou, C.M. et al. (2000) Molecular portraits of human breast tumours. Nature 406, 747-752
88. Alizadeh, A.A. et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511
89. Chen, W. et al. (2008) Mapping translocation breakpoints by next-generation sequencing. Genome Res (May 21, Epub ahead of print)
90. Bapat, S.A. et al. (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65, 3025-3029
91. Bell, D.A. (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18 (Suppl. 2), S19-S32
92. Crum, C.P. et al. (2007) The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19, 3-9